AbbVie price target raised to $250 from $245 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $250 from $245 and keeps an Overweight rating on the shares. Third quarter results are expected to have limited market impact as attention remains on upcoming White House policy developments, key peripheral events, and 2026 outlook commentary, the analyst tells investors in a research note. Any positive reaction to policy clarity is likely to be more muted than in prior quarters, resulting in fewer portfolio positioning changes, the firm says.